Month: April 2025

Company Announcement No. 1153 As of today, all closing conditions for DSV A/S’ pending acquisition of the global freight forwarding and contract logistics business DB Schenker operated by Schenker AG and its affiliates (“Schenker”) from Deutsche Bahn AG have been fulfilled, including approval by the European Commission and the expiration of the applicable waiting period in the US. Please refer to announcement no. 1132 of 13 September 2024. The parties are now able to complete the transaction, which is expected to take place on 30 April 2025. Due to the expected completion of the Schenker acquisition, the interim results for the first quarter of 2025 for DSV A/S, which is scheduled for 29 April 2025, will be postponed to 30 April 2025, where further details and preliminary financial information related to the acquisition of Schenker will...

Ad Hoc Announcement Pursuant to Article 53 of the SIX Exchange Regulation Listing Rules SIKA IS GENERATING GROWTH IN Q1 DESPITE UNPREDICTABLE MARKETS AND CONTINUES INVESTING WORLDWIDEGrowth in local currencies of +1.9% (growth in CHF: +1.1%) Q1 sales of CHF 2,678.3 million (previous year: CHF 2,648.0 million) Organic growth of 0.9% Acquisition effect of 1.0% Targeted investment in future growthAcquisition of Elmich (Singapore), Cromar (UK), and HPS (USA) Opening of new factories in Singapore, Xi’an (China), Quito (Ecuador), and Ust-Kamenogorsk (Kazakhstan)Outlook for fiscal 2025:Sika confirms the outlook, but points to increased market uncertainties arising from potentially prolonged trade conflicts   Expected sales increase in local currencies of 3-6% Over-proportional increase in EBITDA and EBITDA margin of between 19.5%-19.8%Confirmation...

BOSTON, April 14, 2025 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of cancer and autoimmune disease, today announced the pricing of an underwritten public offering of (i) 13,530,780 shares of its common stock and accompanying common stock warrants to purchase an aggregate of 3,382,695 shares of common stock and, (ii) to certain investors in lieu of common stock, pre-funded warrants to purchase 11,469,216 shares of common stock and accompanying common stock warrants to purchase an aggregate of 2,867,304 shares of common stock. Each share of common stock and accompanying common stock warrant are being sold together at a combined public offering price of...

CALGARY, Alberta, April 14, 2025 (GLOBE NEWSWIRE) — PrairieSky Royalty Ltd. (“PrairieSky” or the “Company“) (TSX: PSK) is pleased to announce that its shareholders approved all resolutions at the annual general meeting of shareholders of the Company held on April 14, 2025 (the “Meeting“) in Calgary, Alberta. The resolutions approved at the Meeting were as follows: The resolution to appoint the seven (7) nominees as directors of the Company to serve until the next annual meeting of shareholders of the Company, or until their successors are elected or appointed, was passed by way of ballot and each of the directors received the following votes for their election:Margaret A. McKenzie 212,802,872 (99.914%)Anna M. Alderson 212,841,516 (99.932%)Anuroop S. Duggal 209,670,592 (98.443%)P....

Public company to operate under new name and concentrate on building, acquiring and operating fertility clinics and the distribution of FDA-cleared INVOcell device Private company to operate as NAYA Therapeutics and focus on clinical development of bifunctional antibodies SARASOTA, Fla., April 14, 2025 (GLOBE NEWSWIRE) — INVO Fertility, Inc., formerly known as NAYA Biosciences, Inc. (the “Company”) (Nasdaq: NAYA), a healthcare services fertility company focused on expanding access to advanced treatment through the establishment, acquisition, and operation of fertility clinics, today announced its decision to separate its fertility and oncology operations. This strategic decision to separate its two principal focus areas is expected to enable both businesses to maximize shareholder value. In connection with the planned separation,...

LA JOLLA, Calif., April 14, 2025 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announces that their CEO, Yuichi Iwaki, MD, Ph.D., and CBO, David H. Crean, Ph.D., will be participating in investor meetings at D. Boral Capital’s, Inaugural DBC Conference on May 14, 2025 at the Plaza Hotel, New York City. The conference will bring together public and private executives with institutional investors, high-net worth individuals, and corporate clients from various sectors including Healthcare & Life Sciences. Drs. Iwaki and Crean will be discussing MediciNova’s leading programs in neurologic and metabologic disorders. For more information about participation in the DBC Conference, visit https://dboralcapital.com/conference. About...

NEW YORK, April 14, 2025 (GLOBE NEWSWIRE) — Vornado Realty Trust (NYSE:VNO) announced today that its 52% owned street retail joint venture has completed a $450 million financing of 1535 Broadway, a premier Times Square retail destination with full blockfront 4K LED signage. The interest only, non–recourse loan carries a fixed rate of 6.90% and matures in May 2030. After transaction costs and reserves, $407 million of the net proceeds from the financing were used to partially redeem Vornado’s Retail JV preferred equity. Vornado Realty Trust is a fully-integrated equity real estate investment trust. CONTACT Thomas J. Sanelli(212) 894-7000 Certain statements contained herein may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not guarantees...

Purchased 9 percent of outstanding shares to build upon four years of successful collaboration on hybrid bonding technology for advanced packaging SANTA CLARA, Calif., April 14, 2025 (GLOBE NEWSWIRE) — Applied Materials, Inc. today announced it has purchased 9 percent of the outstanding shares of the common stock of BE Semiconductor Industries N.V. (Besi), a leading manufacturer of assembly equipment for the semiconductor industry. Applied and Besi have been successfully collaborating since 2020, and recently extended their agreement, to co-develop the industry’s first fully integrated equipment solution for die-based hybrid bonding. Hybrid bonding is becoming a critical technology for advanced packaging of semiconductors as designers and manufacturers race to develop more energy-efficient chips. Hybrid bonding connects chips using...